← Oncology Approval Tracker

FDA DECISION ·

Danziten

nilotinib tartrate · Azurity Pharmaceuticals

FDA approvalNew formulationChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed Philadelphia chromosome-positive chronic-phase CML, or chronic- or accelerated-phase disease resistant or intolerant to prior therapy that included imatinib.

LAMPGEN ANALYSIS

Why it matters

This tablet formulation can be taken with or without food, which changes administration compared with the older nilotinib capsules.

What research teams should watch

Prescribe and verify the formulation-specific dose and continue QT and interaction checks; the products are not interchangeable milligram for milligram.

PRIMARY RECORDS

Sources